$NVDA NEWS
Nvidia stock hits another record as Wall Street stays bullish
NasdaqGS - Nasdaq Real Time Price USD
Sarepta Therapeutics, Inc. (SRPT)
At close: 4:00 PM EDT
After hours: 4:02 PM EDT
Research Analysis
Earnings Estimate
CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 13 | 13 | 15 | 15 |
Avg. Estimate | -0.15 | 1.31 | 1.58 | 11.17 |
Low Estimate | -0.81 | 0.53 | 0.27 | 7.03 |
High Estimate | 0.7 | 2.13 | 3.23 | 16.52 |
Year Ago EPS | -0.46 | 0.47 | -5.8 | 1.58 |
Revenue Estimate
CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 16 | 15 | 19 | 19 |
Avg. Estimate | 410.55M | 572.82M | 1.74B | 3.14B |
Low Estimate | 382.8M | 516M | 1.49B | 2.96B |
High Estimate | 458M | 795.6M | 1.93B | 3.58B |
Year Ago Sales | 331.82M | 396.78M | 1.24B | 1.74B |
Sales Growth (year/est) | 23.70% | 44.40% | 40.00% | 80.40% |
Earnings History
CURRENCY IN USD | 9/30/2023 | 12/31/2023 | 3/31/2024 | 6/30/2024 |
---|---|---|---|---|
EPS Est. | -1.23 | 0.01 | -0.07 | 0 |
EPS Actual | -0.46 | 0.47 | 0.37 | 0.07 |
Difference | 0.77 | 0.46 | 0.44 | 0.07 |
Surprise % | 62.60% | 4,600.00% | 628.60% | -- |
EPS Trend
CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Current Estimate | -0.15 | 1.31 | 1.58 | 11.17 |
7 Days Ago | -0.14 | 1.29 | 1.57 | 11 |
30 Days Ago | -0.14 | 1.29 | 1.55 | 10.93 |
60 Days Ago | -0.16 | 1.35 | 1.59 | 11.21 |
90 Days Ago | 0.92 | 2.18 | 3.42 | 11.3 |
EPS Revisions
CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Up Last 7 Days | -- | 1 | 1 | 1 |
Up Last 30 Days | 1 | 2 | 1 | 3 |
Down Last 7 Days | -- | -- | -- | -- |
Down Last 30 Days | 2 | 1 | 1 | 1 |
Growth Estimates
CURRENCY IN USD | SRPT | Industry | Sector | S&P 500 |
---|---|---|---|---|
Current Qtr. | 67.40% | -- | -- | 3.60% |
Next Qtr. | 178.70% | -- | -- | 7.90% |
Current Year | 127.20% | -- | -- | 2.50% |
Next Year | 607.00% | -- | -- | 13.10% |
Next 5 Years (per annum) | 96.00% | -- | -- | 11.87% |
Past 5 Years (per annum) | -- | -- | -- | -- |
Upgrades & Downgrades
Reiterates | RBC Capital: Outperform to Outperform | 10/21/2024 |
Initiated | Jefferies: Buy | 10/21/2024 |
Reiterates | Needham: Buy to Buy | 10/14/2024 |
Maintains | RBC Capital: Outperform to Outperform | 10/4/2024 |
Reiterates | Cantor Fitzgerald: Neutral to Neutral | 9/20/2024 |
Reiterates | RBC Capital: Outperform to Outperform | 9/19/2024 |
Related Tickers
RNA Avidity Biosciences, Inc.
46.71
-7.41%
ALNY Alnylam Pharmaceuticals, Inc.
292.01
-1.32%
BMRN BioMarin Pharmaceutical Inc.
70.28
+0.24%
RARE Ultragenyx Pharmaceutical Inc.
54.46
-3.20%
APLS Apellis Pharmaceuticals, Inc.
26.88
-4.00%
WVE Wave Life Sciences Ltd.
15.11
-1.31%
IONS Ionis Pharmaceuticals, Inc.
39.00
-1.71%
AXSM Axsome Therapeutics, Inc.
91.50
-1.98%
TGTX TG Therapeutics, Inc.
24.37
+4.55%
JAZZ Jazz Pharmaceuticals plc
113.12
-1.67%